S Siméon1, E Flécher2, M Revest3, M Niculescu4, J-C Roussel5, M Michel6, P Leprince7, P Tattevin8. 1. Department of Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France. 2. Department of Cardio-Thoracic and Vascular Surgery, Pontchaillou University Hospital, Rennes, France. 3. Department of Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; Inserm U835, Rennes-1 University, France. 4. Anaesthesiology Department, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre et Marie Curie, Assistance Publique des Hôpitaux de Paris, France. 5. Department of Cardio-Thoracic and Vascular Surgery, Thorax Institute, Laennec University Hospital, Nantes, France. 6. Department of Cardiovascular Diseases, Laennec University Hospital, Nantes, France. 7. Surgery Department, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre et Marie Curie, Assistance Publique des Hôpitaux de Paris, France. 8. Department of Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; Inserm U835, Rennes-1 University, France. Electronic address: pierre.tattevin@chu-rennes.fr.
Abstract
OBJECTIVES: The implantable left ventricular assist device (LVAD) is a major therapeutic development for end-stage heart failure in selected patients. As their use is expanding, infectious complications are emerging, with limited data available to guide their management. We aimed to better characterize LVAD-related infections. METHODS: We enrolled all consecutive patients diagnosed with LVAD-related infections in three referral centres in France, using a standardized definition of infections in patients with LVAD. Data were collected from medical charts using a standardized questionnaire. RESULTS: Between 2007 and 2012, 159 patients received LVAD for end-stage heart failure. Among them, 36 (22.6%; 5 women, 31 men) presented at least one infectious complication, after a median time of 2.9 months from LVAD implantation (interquartile range, 1.8-7.5), with a median follow up of 12 months (interquartile range 8-17). Main co-morbidities were alcoholism (33%), diabetes (11%) and immunosuppression (11%). Mean age at implantation was 51 (±11) years. LVAD were implanted as bridge-to-transplantation (n=22), bridge-to-recovery (n=8), destination therapy (n=4), or unspecified (n=2). LVAD-related infections were restricted to the driveline exit site (n=17), had loco-regional extension (n=13), or reached the internal pump (n=3). The main bacteria isolated were Staphylococcus aureus (n=20), coagulase-negative staphylococci (n=7), Enterobacteriaceae (n=14), Pseudomonas aeruginosa (n=10) and Corynebacterium sp. (n=7), with polymicrobial infections in 19 cases. LVAD could be retained in all patients, with the use of prolonged antibacterial treatment in 34 (94%), and debridement in 17 (47%). One patient died due to LVAD-associated infection. CONCLUSIONS: LVAD-related infections are common after LVAD implantation, and may be controlled by prolonged antibiotic treatment.
OBJECTIVES: The implantable left ventricular assist device (LVAD) is a major therapeutic development for end-stage heart failure in selected patients. As their use is expanding, infectious complications are emerging, with limited data available to guide their management. We aimed to better characterize LVAD-related infections. METHODS: We enrolled all consecutive patients diagnosed with LVAD-related infections in three referral centres in France, using a standardized definition of infections in patients with LVAD. Data were collected from medical charts using a standardized questionnaire. RESULTS: Between 2007 and 2012, 159 patients received LVAD for end-stage heart failure. Among them, 36 (22.6%; 5 women, 31 men) presented at least one infectious complication, after a median time of 2.9 months from LVAD implantation (interquartile range, 1.8-7.5), with a median follow up of 12 months (interquartile range 8-17). Main co-morbidities were alcoholism (33%), diabetes (11%) and immunosuppression (11%). Mean age at implantation was 51 (±11) years. LVAD were implanted as bridge-to-transplantation (n=22), bridge-to-recovery (n=8), destination therapy (n=4), or unspecified (n=2). LVAD-related infections were restricted to the driveline exit site (n=17), had loco-regional extension (n=13), or reached the internal pump (n=3). The main bacteria isolated were Staphylococcus aureus (n=20), coagulase-negative staphylococci (n=7), Enterobacteriaceae (n=14), Pseudomonas aeruginosa (n=10) and Corynebacterium sp. (n=7), with polymicrobial infections in 19 cases. LVAD could be retained in all patients, with the use of prolonged antibacterial treatment in 34 (94%), and debridement in 17 (47%). One patient died due to LVAD-associated infection. CONCLUSIONS:LVAD-related infections are common after LVAD implantation, and may be controlled by prolonged antibiotic treatment.
Authors: Merilda O Blanco-Guzman; Xiaowen Wang; Justin M Vader; Margaret A Olsen; Erik R Dubberke Journal: Clin Infect Dis Date: 2021-01-27 Impact factor: 9.079
Authors: Ishan Kamat; Harveen Lamba; Casey Hines-Munson; Samuel Hudson; Kenneth Liao; Kenneth L Muldrew; Sabrina Green; Austen Terwilliger; Heidi B Kaplan; Robert F Ramig; Anthony Maresso; Barbara W Trautner Journal: J Surg Res Date: 2021-11-27 Impact factor: 2.417
Authors: Nelianne J Verkaik; Yunus C Yalcin; Hannelore I Bax; Alina A Constantinescu; Jasper J Brugts; Olivier C Manintveld; Ozcan Birim; Peter D Croughs; Ad J J C Bogers; Kadir Caliskan Journal: Front Med (Lausanne) Date: 2022-05-24
Authors: Radoslav Zinoviev; Christopher K Lippincott; Sara C Keller; Nisha A Gilotra Journal: Open Forum Infect Dis Date: 2020-04-17 Impact factor: 3.835